trending Market Intelligence /marketintelligence/en/news-insights/trending/QE_nHrYxALXOP9lu4r42sw2 content esgSubNav
In This List

Novartis sells Indian rights to some medicine brands

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


Novartis sells Indian rights to some medicine brands

Novartis AG sold the Indian rights to some of its medicine brands to Mauritius-based private equity firm Samara Capital Inc., a company spokesperson said.

The sale includes the rights to Cofvector, Monkezin and Glyred along with exclusive licenses to Curam, Foristal and Gretacal.

The financial terms of the deal were not disclosed.